1064
Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness.
 ( adverse event: developed ,  he: Subject, he: Subject.Gender, acute vision loss and change of consciousness: Effect, intravitreal injection of bevacizumab (1.25 mg in 0.1 ml),: Treatment, intravitreal injection: Treatment.Route, bevacizumab: Treatment.Drug, 1.25 mg in 0.1 ml: Treatment.Dosage) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: developed ,  he: Subject, he: Subject.Gender, acute vision loss and change of consciousness: Effect, intravitreal injection of bevacizumab (1.25 mg in 0.1 ml),: Treatment, intravitreal injection: Treatment.Route, bevacizumab: Treatment.Drug, 1.25 mg in 0.1 ml: Treatment.Dosage) 